Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of subcutaneous MOA-728 (methylnaltrexone bromide) in opioid-induced constipation
2008-005935-14Phase 3Completed
- Sponsor
- Wyeth
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of methylnaltrexone in opioid-induced constipation (OIC) and constipation, sponsored by Wyeth. Primary endpoint: Long-term safety and tolerability of subcutaneous methylnaltrexone bromide. Started Feb 2009; status: completed.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced constipation (OIC)constipation
Beyond the preview
Go deeper on 2008-005935-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005935-14.